Back to Search
Start Over
Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
- Source :
- Blood; November 2022, Vol. 140 Issue: 1, Number 1 Supplement 1 p4642-4645, 4p
- Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 140
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs62758422
- Full Text :
- https://doi.org/10.1182/blood-2022-164828